Report ID: SQMIG15E2266
Report ID:
SQMIG15E2266 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
67 |
Figures:
75
North America dominated the market with a 36.2% revenue share in 2022. This is attributable to the FDA's approval of the use of goods including sodium chondroitin sulfate as well as the expansion of the American pharmaceutical sector. Demand is also expected to be fueled by factors including the rising prevalence of osteoarthritis, rising use of cholesterol medication, cataract surgery, or formulations for eye drops. A few companies in Europe use chondroitin sulfate, but those that do include those in the pharmaceutical, cosmetics, food, animal feed, and veterinary fields. In dietary supplements, chondroitin sulfate is a substitute medicine used to treat osteoarthritis.
The market in Europe is expected to grow over the forecasted period as a result of more people using medications and nutraceuticals that include sodium chondroitin sulfate. Osteoarthritis, the relief of joint pain, the treatment of heart issues and high cholesterol, and the preparation of eye drops are the usual uses for chondroitin sulfate. In developing countries like China and India, where the aging population is rising, osteoarthritis and other joint health-related issues are more common. The rising frequency of osteoarthritis and its expanding involvement in the treatment of numerous medical illnesses are predicted to raise demand for sources in the Asia Pacific pharmaceutical sector.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG15E2266